| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0028 | 1 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |